Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Public ClinicalTrials.gov record NCT02910583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
Study identification
- NCT ID
- NCT02910583
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 323 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2016 (Actual)
- Primary completion
- Nov 12, 2020 (Actual)
- Completion
- Mar 27, 2024 (Actual)
- Last update posted
- Sep 10, 2026
2016 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 1142-0047 | Duarte | California | 91010 | — |
| Moores Cancer Center at UC San Diego /ID# 1142-0241 | La Jolla | California | 92093 | — |
| UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 1142-0008 | Orange | California | 92868-3201 | — |
| Norton Cancer Center /ID# 1142-0071 | Louisville | Kentucky | 40202 | — |
| Rutgers Cancer Institute of New Jersey /ID# 1142-1193 | New Brunswick | New Jersey | 08901 | — |
| Northwell Health/Long Island Jewish Hospital /ID# 1142-0350 | New Hyde Park | New York | 11042 | — |
| New York Presbyterian Hospital/Weill Cornell Med College /ID# 1142-0200 | New York | New York | 10021 | — |
| University of Rochester Cancer Center /ID# 1142-0127 | Rochester | New York | 14642-0001 | — |
| Charlotte-Mecklenberg Hospital, Carolinas Healthcare System, Levine Cancer Inst /ID# 1142-0733 | Charlotte | North Carolina | 28203 | — |
| Cleveland Clinic Foundation /ID# 1142-0739 | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania /ID# 1142-0069 | Philadelphia | Pennsylvania | 19104 | — |
| Tennessee Oncology - Chattanooga /ID# 1142-0123 | Chattanooga | Tennessee | 37404-1108 | — |
| MD Anderson Cancer Center /ID# 1142-0032 | Houston | Texas | 77030 | — |
| Swedish Cancer Institute /ID# 1142-0114 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02910583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02910583 live on ClinicalTrials.gov.